Noreen Fulton

2.3k total citations
42 papers, 1.2k citations indexed

About

Noreen Fulton is a scholar working on Molecular Biology, Hematology and Oncology. According to data from OpenAlex, Noreen Fulton has authored 42 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Molecular Biology, 18 papers in Hematology and 12 papers in Oncology. Recurrent topics in Noreen Fulton's work include Acute Myeloid Leukemia Research (15 papers), Acute Lymphoblastic Leukemia research (7 papers) and CAR-T cell therapy research (5 papers). Noreen Fulton is often cited by papers focused on Acute Myeloid Leukemia Research (15 papers), Acute Lymphoblastic Leukemia research (7 papers) and CAR-T cell therapy research (5 papers). Noreen Fulton collaborates with scholars based in United States, Japan and Germany. Noreen Fulton's co-authors include E L Kaplan, Thomas A. Brasitus, Theresa P. Pretlow, Francis H. Straus, Carol A. Westbrook, Wendy Stock, Edwin L. Kaplan, Hongtao Liu, T Yäshiro and Stephen Horrigan and has published in prestigious journals such as Journal of Clinical Oncology, Blood and JNCI Journal of the National Cancer Institute.

In The Last Decade

Noreen Fulton

42 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Noreen Fulton United States 20 460 457 304 225 192 42 1.2k
L. Austin Doyle United States 12 407 0.9× 338 0.7× 247 0.8× 85 0.4× 236 1.2× 35 922
Jan J. Koornstra Netherlands 18 524 1.1× 413 0.9× 473 1.6× 217 1.0× 424 2.2× 32 1.5k
Niall Swan Ireland 18 453 1.0× 702 1.5× 158 0.5× 108 0.5× 322 1.7× 59 1.4k
Nisha Nanda United States 14 235 0.5× 286 0.6× 102 0.3× 444 2.0× 137 0.7× 33 1.4k
Preston D. Steen United States 18 579 1.3× 259 0.6× 125 0.4× 79 0.4× 120 0.6× 47 1.0k
S. Bretti Italy 13 391 0.8× 449 1.0× 124 0.4× 53 0.2× 250 1.3× 33 1.3k
Anna Enjuanes Spain 21 330 0.7× 373 0.8× 365 1.2× 32 0.1× 121 0.6× 36 1.1k
Danielle Diarra Austria 10 390 0.8× 671 1.5× 129 0.4× 137 0.6× 113 0.6× 14 1.7k
Joji Yamamoto Japan 17 337 0.7× 171 0.4× 216 0.7× 86 0.4× 381 2.0× 39 997
Nicole Watson Australia 14 242 0.5× 199 0.4× 179 0.6× 567 2.5× 98 0.5× 23 1.3k

Countries citing papers authored by Noreen Fulton

Since Specialization
Citations

This map shows the geographic impact of Noreen Fulton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Noreen Fulton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Noreen Fulton more than expected).

Fields of papers citing papers by Noreen Fulton

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Noreen Fulton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Noreen Fulton. The network helps show where Noreen Fulton may publish in the future.

Co-authorship network of co-authors of Noreen Fulton

This figure shows the co-authorship network connecting the top 25 collaborators of Noreen Fulton. A scholar is included among the top collaborators of Noreen Fulton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Noreen Fulton. Noreen Fulton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Liang, Guanghao, Qiancheng You, Kirk E. Cahill, et al.. (2023). Cellular Composition and 5hmC Signature Predict the Treatment Response of AML Patients to Azacitidine Combined with Chemotherapy. Advanced Science. 10(23). e2300445–e2300445. 8 indexed citations
2.
3.
Fulton, Noreen, et al.. (2020). Abstract 4492: Characterization of the T-Cell receptor repertoire in patients with acute myeloid leukemia treated with 5-Azacytidine plus chemotherapy. Cancer Research. 80(16_Supplement). 4492–4492. 1 indexed citations
4.
Cahill, Kirk E., Yasmin Karimi, Theodore Karrison, et al.. (2020). A phase 1 study of azacitidine with high-dose cytarabine and mitoxantrone in high-risk acute myeloid leukemia. Blood Advances. 4(4). 599–606. 8 indexed citations
5.
Wang, Amy, Howard Weiner, Margaret Green, et al.. (2018). A phase I study of selinexor in combination with high-dose cytarabine and mitoxantrone for remission induction in patients with acute myeloid leukemia. Journal of Hematology & Oncology. 11(1). 4–4. 50 indexed citations
6.
Liu, Hongtao, Yuanyuan Zha, Noura J. Choudhury, et al.. (2018). WT1 peptide vaccine in Montanide in contrast to poly ICLC, is able to induce WT1-specific immune response with TCR clonal enrichment in myeloid leukemia. Experimental Hematology and Oncology. 7(1). 1–1. 18 indexed citations
7.
Alachkar, Houda, Gregory Malnassy, Jae‐Hyun Park, et al.. (2015). T-LAK cell-originated protein kinase presents a novel therapeutic target inFLT3-ITD mutated acute myeloid leukemia. Oncotarget. 6(32). 33410–33425. 21 indexed citations
8.
Tamura, Kenji, Gregory Malnassy, Noreen Fulton, et al.. (2015). Targeting Suppressor of Variegation 3-9 Homologue 2 (SUV39H2) in Acute Lymphoblastic Leukemia (ALL). Translational Oncology. 8(5). 368–375. 19 indexed citations
9.
Odenike, Olatoyosi, Anna B. Halpern, Lucy A. Godley, et al.. (2014). A phase I and pharmacodynamic study of the histone deacetylase inhibitor belinostat plus azacitidine in advanced myeloid neoplasia. Investigational New Drugs. 33(2). 371–379. 10 indexed citations
10.
Fulton, Noreen, Jeffrey Johnson, Lawrence D. Kaplan, et al.. (2013). Minimal Residual Disease (MRD) Status Following Induction Chemo-Immunotherapy Predicts Progression-Free Survival In Mantle Cell Lymphoma (MCL): CALGB 50403 (Alliance). Blood. 122(21). 3002–3002. 2 indexed citations
11.
Sharma, Arun K., Natalie J. Fuller, Noreen Fulton, et al.. (2009). Defined Populations of Bone Marrow Derived Mesenchymal Stem and Endothelial Progenitor Cells for Bladder Regeneration. The Journal of Urology. 182(4S). 1898–1905. 34 indexed citations
12.
Gomes, Ignatius, Tiffany Sharma, Seby Edassery, et al.. (2002). Novel transcription factors in human CD34 antigen–positive hematopoietic cells. Blood. 100(1). 107–119. 31 indexed citations
13.
Hu, Zhenbo, Ignatius Gomes, Stephen Horrigan, et al.. (2001). A novel nuclear protein, 5qNCA (LOC51780) is a candidate for the myeloid leukemia tumor suppressor gene on chromosome 5 band q31. Oncogene. 20(47). 6946–6954. 62 indexed citations
14.
15.
16.
Younes, Nidal, Noreen Fulton, Reiko Tanaka, et al.. (1997). The presence of K‐12 ras mutations in duodenal adenocarcinomas and the absence of ras mutations in other small bowel adenocarcinomas and carcinoid tumors. Cancer. 79(9). 1804–1808. 6 indexed citations
17.
Younes, Nidal, Noreen Fulton, Reiko Tanaka, et al.. (1997). The presence of K-12ras mutations in duodenal adenocarcinomas and the absence ofras mutations in other small bowel adenocarcinomas and carcinoid tumors. Cancer. 79(9). 1804–1808. 39 indexed citations
18.
Yäshiro, T, Noreen Fulton, Hisato Hara, et al.. (1993). Comparison of mutations of ras oncogene in human pancreatic exocrine and endocrine tumors.. PubMed. 114(4). 758–63; discussion 763. 70 indexed citations
19.
Pretlow, Theresa P., et al.. (1993). K-ras Mutations in Putative Preneoplastic Lesions in Human Colon. JNCI Journal of the National Cancer Institute. 85(24). 2004–2007. 181 indexed citations
20.
Schark, Claudia, Noreen Fulton, Tohru Yashiro, et al.. (1992). The value of measurement of RAS oncogenes and nuclear DNA analysis in the diagnosis of Hürthle cell tumors of the thyroid. World Journal of Surgery. 16(4). 745–751. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by L. Austin Doyle Breakdown of academic impact, for papers by Jan J. Koornstra Breakdown of academic impact, for papers by Niall Swan Breakdown of academic impact, for papers by Nisha Nanda Breakdown of academic impact, for papers by Preston D. Steen Breakdown of academic impact, for papers by S. Bretti Breakdown of academic impact, for papers by Anna Enjuanes Breakdown of academic impact, for papers by Danielle Diarra Breakdown of academic impact, for papers by Joji Yamamoto Breakdown of academic impact, for papers by Nicole Watson
Rankless by CCL
2026